These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36708537)

  • 1. Pituitary adenomas with multiple cell lineage combinations: clinicopathological features and short-term prognosis.
    Tang H; Wang X; Bie Z; Yang Z; Wang B; Li S; Liu P
    J Neurosurg; 2023 Sep; 139(3):810-821. PubMed ID: 36708537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
    Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
    Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
    Wang X; Tang H; Bie Z; Wang Y; Yuan R; Zhang Z; Xiong Z; Yang Z; Bi Z; Wang B; Liu P
    Neurosurgery; 2024 Jan; ():. PubMed ID: 38289085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the 2022 WHO Classification of Pituitary Tumors.
    Asa SL; Mete O; Perry A; Osamura RY
    Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
    Dottermusch M; Schüller U; Hagel C; Saeger W
    Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
    Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
    Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
    Kurosaki M
    No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
    Xie J; Wu ZB
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Pathological Aspects of Silent Pituitary Adenomas.
    Drummond J; Roncaroli F; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2473-2489. PubMed ID: 30020466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
    Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
    Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
    Luo M; Tang R; Wang H
    J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs.
    Vallette-Kasic S; Figarella-Branger D; Grino M; Pulichino AM; Dufour H; Grisoli F; Enjalbert A; Drouin J; Brue T
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3050-6. PubMed ID: 12843142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
    Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
    Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plurihormonal PIT1-lineage pituitary neuroendocrine tumors: a clinicopathological study].
    Duan ZJ; Feng J; Zhao HQ; Wang HD; Gui QP; Zhang XF; Ma Z; Hu ZJ; Xiang L; Qi XL
    Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1017-1024. PubMed ID: 37805393
    [No Abstract]   [Full Text] [Related]  

  • 17. No mutations in TPIT, a corticotroph-specific gene, in human tumoral pituitary ACTH-secreting cells.
    Bucciarelli LG; Pecori Giraldi F; Cavagnini F
    J Endocrinol Invest; 2005 Dec; 28(11):1015-8. PubMed ID: 16483181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.
    Suzuki M; Egashira N; Kajiya H; Minematsu T; Takekoshi S; Tahara S; Sanno N; Teramoto A; Osamura RY
    Endocr Pathol; 2008; 19(1):17-26. PubMed ID: 18228160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
    Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.